Akasi Pharma ApS: Financial statements 2025
CVR: 45364577
Source: annual report 2025, Danish Business Authority
29/01/2025 – 31/12/2025
Akasi Pharma ApS (CVR 45364577) has filed annual accounts for 2025. In 2025, the company reported revenue of DKK 1,026,737 and a net result of DKK -1,626,789. The profit margin was -158.4%. Equity in the 2025 report amounted to DKK -1,570,789.
- Revenue
- DKK 1,026,737
- Gross Profit
- DKK -713,595
- Profit/Loss
- DKK -1,626,789
- Equity
- DKK -1,570,789
- Total Assets
- DKK 2,486,459
Official annual report
How creditworthy is Akasi Pharma ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
As of October 17, 2025, Sophie Holding ApS is registered as an owner of Akasi Pharma ApS with an ownership share of 10%.
As of October 17, 2025, is registered as an owner of Akasi Pharma ApS with an ownership share of 25%.
As of January 29, 2025, Walden Emil Bjørn-Yoshimoto is registered as director of Akasi Pharma ApS.
As of January 29, 2025, Helena Safavi-Hemami is registered as director of Akasi Pharma ApS.
As of January 29, 2025, Walden Holding ApS is registered as an owner of Akasi Pharma ApS with an ownership share of 50%.
Akasi Pharma ApS was founded on January 29, 2025.
About Akasi Pharma ApS
Akasi Pharma ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2025. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Helena Safavi-Hemami and Walden Emil Bjørn-Yoshimoto. The company is owned by Walden Holding ApS, Sophie Holding ApS and Venimic LLC. The company has 4 employees (2026). In 2025, the company reported revenue of DKK 1,026,737 and a net result of DKK -1,626,789. Equity in the 2025 report amounted to DKK -1,570,789.